These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27068298)

  • 1. Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapy.
    Vill K; Müller-Felber W; Teusch V; Blaschek A; Gerstl L; Huetker S; Albert MH
    Neuromuscul Disord; 2016; 26(4-5):322-5. PubMed ID: 27068298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
    Cappellini MD; Bejaoui M; Agaoglu L; Canatan D; Capra M; Cohen A; Drelichman G; Economou M; Fattoum S; Kattamis A; Kilinc Y; Perrotta S; Piga A; Porter JB; Griffel L; Dong V; Clark J; Aydinok Y
    Blood; 2011 Jul; 118(4):884-93. PubMed ID: 21628399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    Dee CM; Cheuk DK; Ha SY; Chiang AK; Chan GC
    Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
    [No Abstract]   [Full Text] [Related]  

  • 5. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
    Efthimia V; Neokleous N; Agapidou A; Economou M; Vetsiou E; Teli A; Perifanis V
    Ann Hematol; 2013 Jan; 92(2):263-5. PubMed ID: 22933235
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
    Chandra J; Chaudhary H; Pemde H; Singh V; Dutta AK
    Ann Trop Paediatr; 2011; 31(1):47-51. PubMed ID: 21262109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Prossomariti L
    Acta Haematol; 2010; 123(2):117-20. PubMed ID: 20068283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron-chelation therapy with oral chelators in patients with thalassemia major.
    Uygun V; Kurtoglu E
    Hematology; 2013 Jan; 18(1):50-5. PubMed ID: 23321010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
    Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
    Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
    Diamantidis MD; Neokleous N; Agapidou A; Vetsiou E; Manafas A; Fotiou P; Vlachaki E
    Int J Hematol; 2016 May; 103(5):537-44. PubMed ID: 26861970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
    Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
    Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.
    Papadopoulos N; Vasiliki A; Aloizos G; Tapinis P; Kikilas A
    Ann Pharmacother; 2010 Jan; 44(1):219-21. PubMed ID: 19934389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors.
    Chueh HW; Sung KW; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ
    Pediatr Blood Cancer; 2012 Mar; 58(3):441-7. PubMed ID: 21638755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastric ulcer in a child treated with deferasirox.
    Bauters T; Mondelaers V; Robays H; Hunninck K; de Moerloose B
    Pharm World Sci; 2010 Apr; 32(2):112-3. PubMed ID: 20063122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.